naloxegol oxalate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
naloxegol oxalate: clinical details
Prescribing considerations
- Confirm constipation is opioid-induced and laxative response has been inadequate.
- Review renal and hepatic function, gastrointestinal integrity, interacting medicines and ongoing need for systemic opioids.
- Use caution with methadone, clinically important blood–brain barrier disruption, recent myocardial infarction, symptomatic heart failure or other significant cardiovascular disease.
- Severe hepatic impairment is not recommended; renal impairment and moderate CYP3A4 inhibition require product-specific prescribing adjustment.
- Stop treatment when systemic opioid therapy stops.
Contraindications and cautions
- Hypersensitivity to naloxegol, an excipient or another opioid antagonist.
- Known or suspected gastrointestinal obstruction, or increased risk of recurrent obstruction.
- Underlying cancer associated with heightened perforation risk, including gastrointestinal or peritoneal malignancy, recurrent or advanced ovarian cancer, or VEGF-inhibitor treatment.
- Concomitant strong CYP3A4 inhibition.
Monitoring
- Assess constipation response and gastrointestinal tolerability.
- Investigate severe, persistent or worsening abdominal pain or diarrhoea promptly.
- Monitor for opioid withdrawal or reduced analgesia, especially with blood–brain barrier disruption or methadone.
- Reassess renal or hepatic status and the interaction profile when clinical circumstances or medicines change.
Clinical pharmacology
Naloxegol is a PEGylated naloxone derivative and neutral mu-opioid receptor antagonist. Reduced passive permeability and P-glycoprotein-mediated efflux restrict central nervous system penetration. It is metabolised mainly through CYP3A4; renal excretion of unchanged medicine is a minor clearance pathway.
Formulation and product differences
- The tablet may be swallowed whole or crushed and dispersed in water.
- Administration through a suitable nasogastric tube is supported.
- The selected formulation is essentially sodium-free.
naloxegol oxalate preparations and strengths
Tablet
Route: Oral
Strengths: 12.5 mg, 25 mg
naloxegol oxalate interactions
Check all prescribed, over-the-counter and herbal products before treatment. Important examples include:
Strong CYP3A4 inhibitors, including clarithromycin, ketoconazole, itraconazole and some HIV protease inhibitors
They can greatly increase naloxegol exposure; combined use is contraindicated.
Moderate CYP3A4 inhibitors, including diltiazem and verapamil
They increase naloxegol exposure and require prescriber review and adjustment.
Strong CYP3A4 inducers, including carbamazepine, rifampicin and St John’s wort
They can substantially reduce naloxegol exposure, so combined use is not recommended.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.